CDC reports 27% decline in overdose deaths last year

In what seems *** significant step forward in pain management, the US Food and Drug Administration has approved *** new non-opioid painkiller for treating short term pain in adults. The drugscetragine, branded as Serovva works by targeting pain signals before they reach the brain, offering relief for moderate to severe pain without the addictive. Potential of opioids. Its maker Vertex Pharmaceuticals, says it marks *** breakthrough in treating pain while addressing the ongoing opioid crisis. The FDA's approval comes after successful clinical trials showing Jourovac's reduced pain following surgery. This approval is hailed as an important milestone in acute pain management. As the US continues to battle *** widespread opioid addiction crisis, according to the CDC, nearly 82,000 opioid involved overdose deaths occurred in 2022 alone. The BBC reports Jourova will be priced at $15.50 per capsule, though it remains unclear whether the drug is safe and effective for children.

Updated: 10:14 AM CDT May 14, 2025

Editorial Standards ⓘ

CDC reports 27% decline in overdose deaths last year

Updated: 10:14 AM CDT May 14, 2025

Editorial Standards ⓘ

There were 30,000 fewer U.S. drug overdose deaths in 2024 than the year before — the largest one-year decline ever recorded.An estimated 80,000 people died from overdoses last year, according to provisional Centers for Disease Control and Prevention data released Wednesday. That’s down 27% from the 110,000 in 2023.The CDC has been collecting comparable data for 45 years. The previous largest one-year drop was 4% in 2018, according to the agency’s National Center for Health Statistics.All but two states saw declines last year — with some of the biggest in Ohio, West Virginia and other states that have been hard-hit in the nation's decades-long overdose epidemic.Experts say more research needs to be done to understand what drove the reduction, but they mention several possible factors. Among the most cited:— Increased availability of the overdose-reversing drug naloxone.— Expanded addiction treatment.— Shifts in how people use drugs.— The growing impact of billions of dollars in opioid lawsuit settlement money.— The number of at-risk Americans is shrinking, after waves of deaths in older adults and a shift in teens and younger adults away from the drugs that cause most deaths.Still, annual overdose deaths are higher than they were before the COVID-19 pandemic. And some experts worry that the recent decline could be slowed or stopped by reductions in federal funding and the public health workforce, or a shift away from the strategies that seem to be working.“Now is not the time to take the foot off the gas pedal,” said Dr. Daniel Ciccarone, a drug policy expert at the University of California, San Francisco.The provisional numbers are estimates of everyone who died of overdoses in the U.S., including noncitizens. That data is still being processed, and the final numbers can sometimes differ a bit. But it’s clear that there was a huge drop last year.Experts note that there have been past moments when U.S. overdose deaths seemed to have plateaued or even started to go down, only to rise again. That happened in 2018.But there are reasons to be optimistic.Naloxone has become more widely available, in part because of the introduction of over-the-counter versions that don’t require prescriptions.Meanwhile, drug manufacturers, distributors, pharmacy chains and other businesses have settled lawsuits with state and local governments over the painkillers that were a main driver of overdose deaths in the past. The deals over the last decade or so have promised about $50 billion over time, with most of it required to be used to fight addiction.Another settlement that would be among the largest, with members of the Sackler family who own OxyContin maker Purdue Pharma agreeing to pay up to $7 billion, could be approved this year.The money, along with federal taxpayer funding, is going to a variety of programs, including supportive housing and harm reduction efforts, such as providing materials to test drugs for fentanyl, the biggest driver of overdoses now.But what each state will do with that money is currently at issue. “States can either say, ‘We won, we can walk away’” in the wake of the declines or they can use the lawsuit money on naloxone and other efforts, said Regina LaBelle, a former acting director of the Office of National Drug Control Policy. She now heads an addiction and public policy program at Georgetown University.President Donald Trump’s administration views opioids as largely a law enforcement issue and as a reason to step up border security. That worries many public health leaders and advocates.“We believe that taking a public health approach that seeks to support — not punish — people who use drugs is crucial to ending the overdose crisis,” said Dr. Tamara Olt, an Illinois woman whose 16-year-old son died of a heroin overdose in 2012. She is now executive director of Broken No Moore, an advocacy organization focused on substance use disorder.Olt attributes recent declines to the growing availability of naloxone, work to make treatment available, and wider awareness of the problem.Kimberly Douglas, an Illinois whose 17-year-old son died of an overdose in 2023, credited the growing chorus of grieving mothers. “Eventually people are going to start listening. Unfortunately, it's taken 10-plus years.”

There were 30,000 fewer U.S. drug overdose deaths in 2024 than the year before — the largest one-year decline ever recorded.

An estimated 80,000 people died from overdoses last year, according to provisional released Wednesday. That’s down 27% from the 110,000 in 2023.

The CDC has been collecting comparable data for 45 years. The previous largest one-year drop was 4% in 2018, according to the agency’s National Center for Health Statistics.

All but two states saw declines last year — with some of the biggest in Ohio, West Virginia and other states that have been hard-hit in the nation's decades-long overdose epidemic.

Experts say more research needs to be done to understand what drove the reduction, but they mention several possible factors. Among the most cited:

— Increased availability of the overdose-reversing drug naloxone.

— Expanded addiction treatment.

— Shifts in how people use drugs.

— The growing impact of billions of dollars in opioid lawsuit settlement money.

— The number of at-risk Americans is shrinking, after waves of deaths in older adults and a shift in teens and younger adults away from the drugs that cause most deaths.

Still, annual overdose deaths are higher than they were before the COVID-19 pandemic. And some experts worry that the recent decline could be slowed or stopped by reductions in federal funding and the public health workforce, or a shift away from the strategies that seem to be working.

“Now is not the time to take the foot off the gas pedal,” said Dr. Daniel Ciccarone, a drug policy expert at the University of California, San Francisco.

The provisional numbers are estimates of everyone who died of overdoses in the U.S., including noncitizens. That data is still being processed, and the final numbers can sometimes differ a bit. But it’s clear that there was a huge drop last year.

Experts note that there have been past moments when U.S. overdose deaths seemed to have plateaued or even started to go down, only to rise again. That happened in 2018.

But there are reasons to be optimistic.

has become more widely available, in part because of the introduction of over-the-counter versions that don’t require prescriptions.

Meanwhile, drug manufacturers, distributors, pharmacy chains and other businesses have settled lawsuits with state and local governments over the painkillers that were a main driver of overdose deaths in the past. The deals over the last decade or so have promised about $50 billion over time, with most of it required to be used to fight addiction.

Another settlement that would be among the largest, with members of the Sackler family who own OxyContin maker Purdue Pharma agreeing to pay up to $7 billion, could be approved this year.

The money, along with federal taxpayer funding, is going to a variety of programs, including supportive housing and harm reduction efforts, such as providing materials to test drugs for fentanyl, the biggest driver of overdoses now.

But what each state will do with that money is currently at issue. “States can either say, ‘We won, we can walk away’” in the wake of the declines or they can use the lawsuit money on naloxone and other efforts, said Regina LaBelle, a former acting director of the Office of National Drug Control Policy. She now heads an addiction and public policy program at Georgetown University.

President Donald Trump’s administration views opioids as largely a law enforcement issue and as a reason to step up border security. That worries many public health leaders and advocates.

“We believe that taking a public health approach that seeks to support — not punish — people who use drugs is crucial to ending the overdose crisis,” said Dr. Tamara Olt, an Illinois woman whose 16-year-old son died of a heroin overdose in 2012. She is now executive director of Broken No Moore, an advocacy organization focused on substance use disorder.

Olt attributes recent declines to the growing availability of naloxone, work to make treatment available, and wider awareness of the problem.

Kimberly Douglas, an Illinois whose 17-year-old son died of an overdose in 2023, credited the growing chorus of grieving mothers. “Eventually people are going to start listening. Unfortunately, it's taken 10-plus years.”

��vlog